July 29, 2026 Incyte Corp's Opzelura® Secures EU Approval: A Breakthrough for Moderate Atopic Dermatitis Treatment Incyte Corporation's Opzelura® has received EU approval as the first steroid-free topical JAK inhibitor for moderate atopic dermatitis in adults. Supported by clinical studies, Opzelura shows significant efficacy in alleviating symptoms and improving quality of life for patients inadequately treated by traditional therapies.
July 28, 2026 Incyte Corporation Reports Strong Q2 2026 Financial Results Incyte Corporation reported impressive financial results for Q2 2026, with net income rising to $585.6 million and total revenue reaching $1.67 billion. The company attributes this growth to strong sales of its key products and recent product approvals, despite facing regulatory challenges.
July 28, 2026 Incyte Corp Reports Strong Q2 2026 Results and Strategic Advancements Incyte Corporation's Q2 2026 financial results reveal a 38% increase in total revenue and significant advancements in drug development, particularly in Hematology and Oncology. CEO Bill Meury emphasizes strategic acquisitions and a strong pipeline, positioning the company for future growth.
July 17, 2026 Incyte Corp to Showcase Promising Data at ESMO Congress 2026 Incyte Corporation will showcase its oncology innovations at ESMO Congress 2026, presenting promising data on therapies targeting advanced cancers. Key highlights include a KRAS G12D inhibitor and a TGFβR2×PD-1 bispecific antibody, among others, reflecting Incyte's commitment to advancing cancer treatment.
July 13, 2026 Incyte Corp Reports Promising Phase 1/2 Data for VGA039 (Latarcibart) at ISTH 2026 Incyte Corp has announced promising Phase 1/2 data for VGA039 (latarcibart) at ISTH 2026, indicating significant efficacy and safety in treating von Willebrand disease. The study showed an 81% reduction in annualized bleeding rates, with potential for redefining prophylactic care for patients.
July 08, 2026 Incyte Corp Set to Announce Second Quarter Financial Results Incyte Corporation will announce its Q2 2026 financial results on July 28, followed by a conference call at 8:00 a.m. ET. Investors can participate live or access a replay for key insights into the company's performance.
July 06, 2026 Incyte Corp Expands Hematology Portfolio with Vega Therapeutics Acquisition Incyte Corporation has acquired Vega Therapeutics to enhance its hematology portfolio with VGA039, a monoclonal antibody in Phase 3 trials for von Willebrand disease. This acquisition aims to improve treatment options for patients, potentially offering a novel once-monthly therapy, marking a significant advancement in bleeding disorder management.
June 26, 2026 Incyte Corp Sees Positive CHMP Opinion for Opzelura® Cream in Atopic Dermatitis Incyte Corporation's Opzelura® cream has received a positive opinion from the CHMP for treating adults with moderate atopic dermatitis, providing a new option for patients. Clinical studies show significant efficacy and a favorable safety profile, addressing a critical gap in existing treatments.
June 19, 2026 Incyte Corp Secures Approval for Minjuvi® in Japan: A New Hope for DLBCL Patients Incyte Corp's Minjuvi® has been approved for use in Japan, providing a new treatment option for patients with relapsed or refractory DLBCL. Backed by clinical trials showing promising efficacy, this approval marks a significant advancement in cancer care.
June 13, 2026 Incyte Corp Reports Promising Phase 1 Data for INCA033989 at EHA 2026 Incyte Corporation presented encouraging Phase 1 data for INCA033989, a monoclonal antibody targeting mutant calreticulin, at EHA 2026. The results highlight its efficacy in treating myelofibrosis and essential thrombocythemia, showing significant improvements in clinical endpoints and safety profiles, paving the way for future regulatory advancements.
June 13, 2026 Incyte Corp Announces Promising Phase 3 Trial Results for Tafasitamab at EHA Congress Incyte Corp's Phase 3 frontMIND trial shows tafasitamab combined with lenalidomide significantly improves progression-free survival in untreated high-risk DLBCL and HGBL patients. The treatment demonstrates a promising safety profile and is expected to redefine first-line therapy standards.
June 08, 2026 Incyte Corp Expands Hematology Portfolio with Acquisition of Vega Therapeutics Incyte Corporation has announced its acquisition of Vega Therapeutics for $1.25 billion to enhance its hematology portfolio with VGA039, a new therapy for von Willebrand disease. This strategic move positions Incyte to address significant unmet needs in bleeding disorders with innovative treatments.
May 26, 2026 Incyte Corp to Showcase Innovations at Goldman Sachs Healthcare Conference Incyte Corporation will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing its drug development innovations. The live webcast will provide insights into the company's future strategies and commitment to patient care.
May 20, 2026 Incyte Expands Collaboration with Genesis Molecular AI to Supercharge Drug Discovery Incyte Corporation has expanded its collaboration with Genesis Molecular AI to leverage AI for drug discovery, sharing proprietary data to enhance AI model performance. This partnership aims to accelerate the development of innovative therapies while potentially generating significant financial rewards for both companies.
May 07, 2026 Incyte Corp Releases Promising 24-Week Data for Opzelura® in Moderate Atopic Dermatitis Incyte Corporation announced promising 24-week results from the Phase 3 TRuE-AD4 trial for Opzelura in moderate atopic dermatitis, showing significant improvement in patients. The treatment was well-tolerated, with a low incidence of adverse effects, positioning Opzelura as a viable option for patients unresponsive to traditional therapies.
May 06, 2026 Incyte Corporation Grants Inducement Awards to New CFO Incyte Corporation has granted a series of equity inducement awards to new CFO Suky Upadhyay, emphasizing the importance of aligning executive compensation with performance. This strategic move aims to foster long-term commitment and signals confidence in the company's direction as it continues to innovate in the biopharmaceutical space.
May 01, 2026 Incyte Corp Achieves FDA Approval for Jakafi XR™: A New Era in Treatment for Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease Incyte Corporation celebrates FDA approval of Jakafi XR™, a new once-daily treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease. This innovative formulation aims to improve patient compliance and treatment outcomes in hematology.
April 29, 2026 Incyte Corp to Showcase Innovations at May Investor Conferences Incyte Corporation will participate in two major investor conferences in May 2026, showcasing its commitment to transparency and innovation in biopharmaceuticals. The events will provide insights into Incyte's product pipeline and strategic direction, with webcasts available for broader access.
April 28, 2026 Incyte Corp Reports Strong Q1 2026 Financial Results and Strategic Updates Incyte Corporation's Q1 2026 results show a strong financial performance with a 20% increase in net sales, driven by key products like Jakafi® and Opzelura®. The company is focused on innovation and strategic growth, with upcoming product approvals and a solid cash position.
April 28, 2026 Incyte Corp Appoints Suketu Upadhyay as Chief Financial Officer Incyte Corporation has appointed Suketu Upadhyay as Chief Financial Officer, effective May 4, 2026. With extensive experience in the pharmaceutical sector, Upadhyay will oversee financial strategies and capital allocation to drive long-term value creation as the company navigates its growth trajectory.
April 28, 2026 Incyte Corporation Reports Strong Q1 2026 Financial Results Incyte Corporation reported a net income of $303.3 million in Q1 2026, reflecting a significant increase from the previous year. Driven by strong sales of JAKAFI and OPZELURA, total revenue rose to $1.27 billion. The company's robust balance sheet and commitment to R&D position it for future growth despite competitive challenges.
April 21, 2026 Incyte Corp Showcases Innovative Tafasitamab Data Ahead of ASCO 2026 Incyte Corporation will present pivotal data on tafasitamab for newly diagnosed diffuse large B-cell lymphoma at ASCO 2026. The positive Phase 3 results highlight the drug's potential in enhancing treatment options for patients. This marks a significant advancement in Incyte's commitment to oncology innovation.
April 09, 2026 Incyte Corp to Unveil First Quarter Financial Results Incyte Corporation has scheduled its first quarter financial results announcement for April 28, 2026, with a conference call to follow. The event will highlight the company's commitment to innovation in biopharmaceuticals and provide key insights into its performance.
March 28, 2026 Incyte Corp Reports Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa Incyte Corporation reported positive 54-week results from its Phase 3 STOP-HS trials for povorcitinib, showing significant improvements in treating hidradenitis suppurativa. The data revealed high rates of response and enhanced quality of life for patients, paving the way for potential regulatory approvals.
March 25, 2026 Incyte Corp Announces Key Executive Leadership Changes to Propel Growth Strategy Incyte Corp has appointed Dr. Pablo J. Cagnoni as President and Global Head of R&D, along with Dr. Steven Stein as CMO and Mohamed Issa as Head of U.S. Commercial. These leadership changes aim to enhance operational capabilities and drive long-term growth in key therapeutic areas.
March 20, 2026 Incyte Corp Unveils Promising Data on Hidradenitis Suppurativa at AAD 2026 Incyte Corporation presents significant data on povorcitinib for hidradenitis suppurativa at AAD 2026, highlighting its efficacy and safety. The findings promise to enhance treatment options for patients suffering from this challenging condition.
March 06, 2026 Incyte Corp Secures European Commission Approval for Zynyz® in Advanced Squamous Cell Carcinoma Treatment Incyte Corporation has secured European Commission approval for Zynyz® as a first-line treatment for advanced squamous cell carcinoma of the anal canal. This marks a significant milestone in expanding treatment options for this rare cancer, based on promising Phase 3 trial results that demonstrated improved patient outcomes.
February 17, 2026 Incyte Corp. Set to Showcase Innovations at Upcoming Investor Conferences Incyte Corporation is set to present at three major investor conferences in March 2026, highlighting its commitment to biopharmaceutical innovation. The company will offer live webcasts of its presentations, ensuring accessibility for investors and analysts. With a focus on addressing unmet medical needs, Incyte aims to share insights into its strategic objectives and pipeline advancements.
February 10, 2026 Incyte Corp Reports Robust Financial Results for Q4 and Full Year 2025 Incyte Corporation reported a robust 28% revenue increase in Q4 2025, driven by strong product sales and significant pipeline advancements. Full-year revenues reached $5.14 billion, with optimistic projections for 2026, highlighting key products like Jakafi and Opzelura.
February 10, 2026 Incyte Corp's 2025 Annual Report: A Year of Remarkable Growth and Strategic Advancements Incyte Corporation's 2025 annual report illustrates a transformative year with net income increasing to $1.29 billion and significant revenue growth across various regions. The company's strategic investments in R&D and collaborations position it for continued success as it navigates the biopharmaceutical landscape.
January 30, 2026 Incyte Corp. Achieves Significant Milestone with Positive CHMP Opinion for Zynyz® Incyte Corporation has received a positive opinion from the CHMP for Zynyz® as a first-line treatment for advanced squamous cell carcinoma of the anal canal. The recommendation is based on favorable trial results showing significant efficacy when combined with chemotherapy. This milestone could lead to improved treatment options for patients facing this challenging cancer.
January 27, 2026 Incyte Corp Prepares to Unveil Fourth Quarter and Year-End 2025 Financial Results Incyte Corporation will unveil its fourth quarter and year-end 2025 financial results on February 10, 2026. Investors can join the conference call at 8:00 a.m. ET to discuss the company's performance and future strategies.
January 05, 2026 Incyte Corp Reports Promising Results for Tafasitamab in DLBCL Treatment Incyte Corporation announced positive results from its Phase 3 frontMIND trial for tafasitamab in DLBCL treatment, showing improved progression-free survival rates. The study indicates a potential new first-line treatment option for patients, responding to the urgent need for effective therapies in this population.
December 22, 2025 Incyte Corp Makes Strides in Oncology with Minjuvi® Approval in Japan Incyte Corp's Minjuvi® has been approved in Japan for patients with relapsed follicular lymphoma, marking a significant advancement in oncology treatment. Backed by strong clinical trial results, this dual-targeted therapy enhances progression-free survival, addressing critical unmet medical needs.
December 22, 2025 Incyte Corp Achieves Historic Milestone with Zynyz® Approval for Advanced Anal Cancer Treatment in Japan Incyte's Zynyz® has been approved in Japan as the first-line treatment for advanced squamous cell carcinoma of the anal canal, a significant milestone in cancer therapy. Supported by positive clinical trial results, this approval provides new hope for patients facing this aggressive cancer type as Incyte aims to expand its global reach.
December 18, 2025 Incyte Corp Set to Present at 44th Annual J.P. Morgan Healthcare Conference Incyte Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The event will showcase the company's latest advancements and be accessible via live webcast. This participation highlights Incyte’s commitment to innovation in biopharmaceuticals and engagement with investors.
December 17, 2025 Incyte Corp Secures European Commission Approval for Minjuvi®: A Milestone for Follicular Lymphoma Treatment Incyte Corp has received European Commission approval for Minjuvi® (tafasitamab) to treat relapsed follicular lymphoma. This innovative chemotherapy-free option significantly improves progression-free survival and addresses unmet medical needs for patients in Europe.
December 12, 2025 Incyte Corporation Announces Board of Directors Change Incyte Corporation has announced the immediate resignation of Hervé Hoppenot from its Board of Directors, effective immediately. His leadership and contributions have been pivotal in establishing Incyte's prominence in the biopharmaceutical sector, as the company prepares for future innovations.
December 08, 2025 Incyte Corp Presents Promising Data on INCA033989 at ASH 2025 Incyte Corporation presented compelling data on INCA033989, a novel therapy for essential thrombocythemia, at ASH 2025. The clinical trials revealed significant hematologic and molecular responses with a favorable safety profile, highlighting its potential to transform treatment for high-risk patients.
December 07, 2025 Incyte Corp Releases Promising Data for INCA033989 in Myelofibrosis Incyte Corporation announced positive Phase 1 trial data for INCA033989, a monoclonal antibody for myelofibrosis, revealing notable efficacy in both monotherapy and combination therapy. The company plans to initiate a registrational program in 2026 based on these encouraging results.
December 07, 2025 Incyte Corp Receives Breakthrough Therapy Designation for INCA033989 Incyte Corporation announced that its monoclonal antibody, INCA033989, received Breakthrough Therapy designation from the FDA for treating essential thrombocythemia. This first-in-class therapy targets patients with a Type 1 CALR mutation resistant to other treatments, marking a significant advancement in patient care.
December 03, 2025 Incyte Corporation Announces Inducement Grant for New Executive Incyte Corporation has appointed Richard Hoffman as its new Executive Vice President and General Counsel, granting him a comprehensive equity package. This strategic move aims to strengthen the company's leadership team and navigate the complexities of the biopharmaceutical landscape effectively.
December 02, 2025 Incyte Corp Partners with Winnie Harlow to Raise Awareness on Vitiligo Incyte Corporation collaborates with Winnie Harlow to launch 'The Power of Choice' campaign, aimed at raising awareness of vitiligo. Harlow shares her personal experiences to foster understanding and support for those living with the condition.
December 01, 2025 Incyte Corp Welcomes Richard Hoffman as New Executive Vice President and General Counsel Incyte Corporation has welcomed Richard Hoffman as its new Executive Vice President and General Counsel. With over 20 years of legal experience, Hoffman is set to drive Incyte's growth and innovation as the company transitions leadership following Sheila Denton's departure.
November 19, 2025 Incyte Corp to Showcase Innovations at December Investor Conferences Incyte Corporation will participate in two prominent investor conferences in December 2025, focusing on its innovative pipeline and corporate strategies. The presentations will be live-streamed, emphasizing Incyte's commitment to transparency and investor engagement.
November 17, 2025 Incyte Corp Secures Positive CHMP Opinion for Minjuvi® in Treating Follicular Lymphoma Incyte Corporation's Minjuvi® has received a positive opinion from the CHMP for its use in treating relapsed follicular lymphoma. This dual-targeted immunotherapy, if approved, will provide new hope for patients facing limited treatment options in Europe.
November 06, 2025 Incyte Corp Expands *Moments of Clarity* Program to Amplify Patient Voices in Dermatology Incyte Corporation has expanded its Moments of Clarity program to showcase narratives from patients with vitiligo and eczema. The initiative aims to empower individuals and families by sharing their experiences, while promoting Opzelura as a key treatment option.
November 03, 2025 Incyte Corp's Promising Data Presentation at ASH 2025 Incyte Corporation will present over 50 abstracts at the 2025 ASH Annual Meeting, focusing on advancements in blood cancer treatments, particularly for myeloproliferative neoplasms. Key highlights include data on the mutCALR-targeted antibody INCA033989 and other therapies like Axatilimab.
October 30, 2025 Incyte Corp to Showcase Innovations at November Investor Conferences Incyte Corporation is set to present at two major investor conferences in November 2025, detailing its innovative therapeutics and product pipeline. The events will feature live webcasts, ensuring accessibility for all stakeholders.
October 28, 2025 Incyte Corp Reports Strong Third Quarter 2025 Financial Results Incyte Corp's third-quarter 2025 financial results reveal a 20% revenue growth to $1.37 billion, fueled by increased demand for its key products Jakafi and Niktimvo. The company strategically reduced R&D expenses while raising its full-year revenue guidance, positioning itself for continued success in the biopharmaceutical market.
October 28, 2025 Incyte Corporation's Strong Q3 2025 Financial Performance: A Deep Dive Incyte Corporation reported a remarkable Q3 2025 with a net income of $424.2 million, driven by strong sales of JAKAFI, OPZELURA, and NIKTIMVO. The company’s robust financial position is supported by a solid balance sheet and increased cash flow, despite facing challenges like dependency on JAKAFI and potential regulatory changes.
October 19, 2025 Incyte Corp Unveils Promising Phase 1 Results in Oncology Research Incyte Corporation has reported promising Phase 1 clinical trial results for two investigational cancer therapies: INCA33890 for colorectal cancer and INCB161734 for pancreatic cancer. Both treatments showed manageable safety profiles and notable objective response rates, indicating substantial potential for advancing cancer care.
October 08, 2025 Incyte Corp Schedules Third Quarter Financial Results Conference Call Incyte Corporation will hold a conference call on October 28, 2025, to discuss its third-quarter financial results. This event is crucial for investors seeking insights into Incyte's growth strategy in oncology and inflammatory treatments.
September 24, 2025 Incyte Corp Strengthens Leadership with Inducement Grant for New Chief Strategy Officer Incyte Corporation has appointed David H. Gardner as its new Chief Strategy Officer, granting him substantial equity inducement awards. This strategic move aims to align his interests with shareholders while enhancing the company's capacity to tackle unmet medical needs in the biopharmaceutical sector.
September 22, 2025 Incyte Corp Appoints Dave Gardner as Chief Strategy Officer Incyte Corp appoints Dave Gardner as Chief Strategy Officer to enhance its leadership and growth strategy. With over 20 years of biopharma experience, Gardner aims to drive innovation and sustainable value creation.
September 18, 2025 Incyte Corp Secures FDA Approval for Opzelura® in Young Children with Atopic Dermatitis Incyte Corporation has received FDA approval for Opzelura® cream to treat mild to moderate atopic dermatitis in children aged two and older. This breakthrough provides a much-needed, steroid-free treatment option for families facing chronic skin conditions. The approval is supported by positive clinical trial results demonstrating safety and efficacy.
September 17, 2025 Incyte Corp Unveils Promising Phase 3 Data for Povorcitinib in Hidradenitis Suppurativa Incyte Corporation announced promising results from its Phase 3 STOP-HS trials for povorcitinib, showing significant efficacy in treating moderate to severe hidradenitis suppurativa. The data highlights improvements in symptoms and pain management with a favorable safety profile, paving the way for potential regulatory submissions in 2025.
July 29, 2025 Incyte Corporation Reports Strong Financial Recovery in Q2 2025 Incyte Corporation reported a net income of $405 million for Q2 2025, marking a significant turnaround from a net loss in 2024. The company's growth is attributed to strategic product launches and an increase in revenue, despite facing some challenges.
May 15, 2025 Incyte Corp Announces Landmark FDA Approval for Zynyz® in Advanced Anal Cancer Treatment Incyte Corporation's Zynyz® (retifanlimab-dlwr) has received FDA approval as the first-line treatment for inoperable advanced anal cancer. This milestone offers significant improvements in patient outcomes and marks a pivotal moment in treating a historically underserved condition. Incyte is also pursuing international approvals and remains committed to patient support.
May 07, 2025 Incyte Corp Announces Inducement Grants for New Employees Incyte Corporation has approved inducement grants for 60 new employees, featuring RSUs and stock options to enhance talent acquisition. This strategic move underscores Incyte's commitment to innovation in a competitive biopharmaceutical landscape.
May 01, 2025 Incyte Corp Set to Showcase Innovations at BofA Securities Health Care Conference Incyte Corporation will showcase its innovative pipeline at the BofA Securities Health Care Conference on May 13, 2025. The presentation will be streamed live, allowing investors to gain insights into Incyte's strategic initiatives and future prospects in the biopharmaceutical sector.
April 29, 2025 Incyte Corp Reports Strong First Quarter 2025 Financial Results Incyte Corp's Q1 2025 financial results reveal a notable revenue increase of 20%, driven by key products Jakafi and Opzelura. The company also reported significant advancements in its clinical pipeline, positioning itself for continued growth amidst a robust market landscape.
April 29, 2025 Incyte Corporation: Q1 2025 Financial Results Highlight Growth Amid Challenges Incyte Corporation's Q1 2025 report reveals a net income decline despite revenue growth to $1.05 billion, driven by strong JAKAFI sales. Strategic acquisitions and partnerships position Incyte for future success, though challenges including legal issues remain.
April 25, 2025 Incyte Corp. to Showcase Promising Early-Stage Oncology Data at AACR Annual Meeting 2025 Incyte Corporation will showcase promising early-stage oncology data at the AACR Annual Meeting 2025, highlighting new treatments for myeloproliferative neoplasms and ovarian cancer. Key presentations will include innovative therapies enhancing T-cell function and improving patient outcomes.
April 23, 2025 Incyte Corp to Present Pioneering Oncology Data at ASCO 2025 Incyte Corporation will present groundbreaking oncology data at ASCO 2025, featuring key findings from their advanced research on cancer treatments. Highlighted presentations include innovative therapies targeting ovarian cancer, glioblastoma, and squamous cell carcinoma, showcasing Incyte's commitment to transforming cancer care.
April 10, 2025 Incyte Corp to Announce First Quarter Financial Results Incyte Corporation is set to announce its financial results for Q1 2025 on April 29 at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. This event will provide stakeholders with insights into the company's performance and strategic plans moving forward.
April 07, 2025 Incyte Corp Announces Inducement Grants to New Employees Incyte Corporation has awarded RSUs to 24 new employees as part of its inducement strategy to attract top talent. This initiative aligns with the company's mission to develop innovative solutions for patients and strengthens its growth strategy in the biopharmaceutical sector.
March 08, 2025 Incyte Corp Reports Promising Phase 3 Trial Results for Ruxolitinib Cream in Prurigo Nodularis Incyte Corp revealed successful Phase 3 trial results for ruxolitinib cream in treating prurigo nodularis, demonstrating significant itch relief and skin improvement. The company plans to engage with regulators for potential approval.
February 28, 2025 Incyte Corp to Showcase Dermatology Innovations at AAD Annual Meeting Incyte Corporation will present new data at the AAD Annual Meeting 2025, focusing on ruxolitinib cream for prurigo nodularis and axatilimab for chronic GVHD. These advancements aim to address critical dermatological needs and enhance patient outcomes.
February 20, 2025 SWOT Analysis of Incyte Corporation in 2025 This SWOT analysis of Incyte Corporation in 2025 highlights its established market presence, innovative pipeline, and potential growth opportunities. However, the company also faces challenges such as market reliance and intense competition. Understanding these factors is crucial for navigating the dynamic biopharmaceutical landscape.
February 20, 2025 Incyte and Genesis Therapeutics Forge Strategic AI Partnership Incyte Corporation has partnered with Genesis Therapeutics to enhance drug discovery using AI technologies. The collaboration aims to develop innovative small molecule medicines, with significant financial incentives tied to successful milestones.
February 18, 2025 Incyte Corp Set to Showcase Innovations at Upcoming Investor Conferences Incyte Corp is set to present at the Cowen and Leerink Partners healthcare conferences in March 2025, emphasizing its commitment to innovation and investor engagement. The live webcasts will allow broader access to the company's advancements in biopharmaceutical solutions.
February 10, 2025 Incyte Corporation: 2024 Annual Report Analysis Incyte Corporation's 2024 annual report reveals a revenue increase to $4.24 billion, driven by strong product sales, despite a significant decline in net income. The report highlights strategic developments, including the acquisition of Escient Pharmaceuticals and ongoing legal challenges with CMS.
February 10, 2025 Incyte Corporation Reports Strong Year-End Results and Ambitious 2025 Outlook Incyte Corporation reported a 15% revenue increase in 2024, driven by strong sales of Jakafi and Opzelura. The company is optimistic about 2025, anticipating continued growth and significant product launches in its R&D pipeline.
February 07, 2025 Incyte Corp Announces Inducement Grants to New Employees Incyte Corp has awarded restricted stock units to 24 new employees as part of its efforts to attract talent in the biopharmaceutical sector. This strategic move aligns employee interests with shareholders and aims to strengthen Incyte's innovation capabilities in healthcare.
October 29, 2024 Incyte Corporation Reports Strong Q3 2024 Financial Performance Incyte Corporation's Q3 2024 financial results reveal a 23% revenue increase to $1.13 billion, despite a decline in net income. The company is investing heavily in R&D following recent acquisitions and is optimistic about its future growth prospects.
July 30, 2024 Incyte Corporation Reports Q2 2024 Financial Results: A Mixed Bag Amidst Strategic Growth Incyte Corporation's Q2 2024 results reveal revenue growth to $243.1 million driven by JAKAFI, but also a net loss of $143.1 million. The company faces challenges in balancing innovation with financial performance as it expands its product pipeline and navigates competitive risks.
April 30, 2024 Incyte Corporation's Q1 2024 Financial Report: A Promising Surge in Performance Incyte Corporation's Q1 2024 financial report reveals a significant revenue increase to $880.8 million and a net income surge to $169.5 million. The company's strong performance, driven by its hematology and oncology products, highlights its solid market position and commitment to innovation.
